MTX325 is a first-in-class, highly potent, orally bioavailable, brain-penetrant USP30 inhibitor designed to modify the course of Parkinson’s by improving...
Mission will investigate whether genetic ancestry and population-specific differences influence responses to therapies for Parkinson's disease, Primary Progressive Multiple Sclerosis,...
WICHITA, Kan., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Legend Senior Living’s CEO, COO, and CFO took pies in the face...
DENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its boardroom, while its clinical-development...
New multi-phase patient engagement initiative will explore how AI-powered CT analysis can help people living with pulmonary fibrosis better understand...
Brain Prize co-recipient whose research identified CGRP as a central driver of migraine joins to guide development of BETR-001 in...
Synmosa to lead regulatory approvals, market access, distribution and sales in Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and...
SPM-2551 demonstrated robust and durable pharmacological activity following a single low-dose administration in preclinical Duchenne muscular dystrophy (DMD) modelsData support...
New behavioral health category recognizes case management excellence in mental healthSAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Enlyte has named a...
- Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1 -...
NEW YORK, Oct. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines...
NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines...
Preclinical Results at Sheba Medical Center Demonstrate Retinal Recovery with NurExone’s Exosome-based Lead CandidateTORONTO and HAIFA, Israel, Oct. 09, 2026...
Research presented at ISFTD 2026 connects measurements from the living brain with disease patterns confirmed through postmortem analysis Mapping cortical...
Fort Lee, NJ, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
The article explains how different tests evaluate the inner ear, eye movements, and balance function to help investigate dizziness and...
The study will evaluate PoMA™ therapy, Alpheus' drug-led, tumor-selective treatment approach, in patients with butterfly glioblastoma, a particularly aggressive form...
Independent analysis finds $30,474 in modeled median savings per engaged member, per journey through changed treatment pathsFindings remained consistent across...
Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...
Peer-reviewed study of 45 online working adult undergraduates introduces a model linking course design, psychological safety and guided AI use. PHOENIX,...